Relugolix News
Relugolix currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Relugolix with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Ryeqo is indicated in adult women of reproductive age for: - treatment of moderate to severe symptoms of uterine fibroids, - symptomatic treatment of endometriosis in women with a history of previous...
- Evidence level: L5
- Predicted indications (20):
- nephrogenic syndrome of inappropriate antidiuresis (96.1%)
- Smouldering systemic mastocytosis (96.1%)
- systemic mastocytosis (96.1%)
- lymphoadenopathic mastocytosis with eosinophilia (95.9%)
- multiple endocrine neoplasia (95.3%)
- gastrin secretion abnormality (95.0%)
- leprosy (94.5%)
- hypertrichosis (disease) (93.2%)
- malformation syndrome with odontal and/or periodontal component (93.0%)
- syndrome with a Dandy-Walker malformation as major feature (92.9%)
- Ambras type hypertrichosis universalis congenita (92.8%)
- isolated genetic hair shaft abnormality (92.7%)
- Legionnaires' disease (92.5%)
- HIV infectious disease (91.9%)
- multidrug-resistant tuberculosis (91.4%)
- coronary artery disease (91.3%)
- Plasmodium falciparum malaria (91.0%)
- anomalous left coronary artery from the pulmonary artery (90.9%)
- abnormality of glucagon secretion (90.7%)
- simian immunodeficiency virus infection (90.6%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.